DATAR Medical's PainGuard™ Achieved Significant Improvement in Postoperative Pain Treatment in a Clinical Trial

TEL AVIV, Israel, September 30, 2021 (Newswire.com) - DATAR Medical Innovations is a leading company in innovation in treating postoperative pain in outpatients and inpatients through continuous regional anesthesia. DATAR is the developer of the patented PainGuard^TM pumping technology, which mimics intermittent delivery of a manual anesthesia injection, combining the clinical advantages of an efficient manual injection medication spread (for improved pain blockage) with those of continuous therapy delivered by an infusion pump.

DATAR has announced today that it has achieved its first initial clinical milestone pursuant to the company development plan. The company reported that the results of its first clinical trial show a significant (~60%) reduction in opioid use following orthopedic surgical procedures, a market segment estimated at M$900 with CAGR over 7%.

The results also show three major clinical achievements ^(a):

• A significant reduction in the need to use opioids during the first 72h postoperatively.
• A significant improvement of the drug therapy efficacy: over 35% reduction in the amount of medication consumption during the first 72h postoperatively. Hence, therapy duration may be extended up to 120h postoperatively using the same drug volume
• A Lower postoperative pain.

The significant improvement in the drug therapy is a direct outcome of the unique, innovative drug administration regimen implemented by the PainGuard™ pump, which mimics an intermittent delivery of a manual nerve-block injection administered by an experienced anesthesiologist. As a result, a significantly larger portion of the infused drug is actually delivered to the target, close to the nerve plexus.

PainGuard^TM also offers efficient, cost-effective, 24/7 remote outpatient monitoring and enables AI analysis of the actual therapy records to help physicians make better clinical decisions and improve patient outcomes.

"We are very pleased to have reached this milestone, which marks the successful completion of DATAR's first clinical trial. Now that we have shown that the PainGuard™ technology brings significant added value to patients, it is clear that this technology is going to be the industry gold standard for treating postoperative pain of both outpatients and inpatients", said Ofer Shay, Chief Executive Officer of DATAR.

About DATAR Medical Innovation

DATAR is a leading medical device company utilizing its broad knowledge and experience in the field of pain treatment using pumps to develop first-in-class postoperative pain technology.

For additional information, please refer to http://pain-guard.com

Contacts

DATAR Medical Innovation Ltd.
Ofer Shay, CEO
[email protected]
+972-52-2820428

^(a) Evaluations of programmed intermittent bolus (simulating manual injection) infusion versus continuous infusion of ropivacaine in adductor canal block after total knee arthroplasty- An open-label randomized controlled clinical trial
 

Source: DATAR Medical Innovations